Royalty Pharma Plc
$ 50.00
3.14%
17 Apr - close price
- Market Cap 29,640,862,000 USD
- Current Price $ 50.00
- High / Low $ 50.00 / 48.35
- Stock P/E 28.09
- Book Value 15.11
- EPS 1.78
- Next Earning Report 2026-05-06
- Dividend Per Share $0.88
- Dividend Yield 1.82 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.13 %
- 52 Week High 50.00
- 52 Week Low 30.85
About
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$51.78
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-05 | 2025-08-06 | 2025-05-08 | 2025-02-11 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 1.47 | 1.17 | 1.14 | 1.06 | 1.15 | 0.92 | 0.96 | 0.98 | 1.52 | 0.79 | 0.84 | 1.6 |
| Estimated EPS | 1.33 | 1.04 | 1.03 | 0.95 | 1.05 | 0.93 | 0.97 | 0.98 | 1 | 0.77 | 0.81 | 1.27 |
| Surprise | 0.14 | 0.13 | 0.11 | 0.11 | 0.1 | -0.01 | -0.01 | 0 | 0.52 | 0.02 | 0.03 | 0.33 |
| Surprise Percentage | 10.5263% | 12.5% | 10.6796% | 11.5789% | 9.5238% | -1.0753% | -1.0309% | 0% | 52% | 2.5974% | 3.7037% | 25.9843% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.22 |
| Currency | USD |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-10 | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-13 | 2024-06-14 | 2024-03-15 |
| Amount | $0.235 | $0.235 | $0.22 | $0.22 | $0.22 | $0.22 | $0.21 | $0.21 | $0.21 | $0.21 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RPRX
2026-04-17 12:40:14
Royalty Pharma (Nasdaq: RPRX) has declared a dividend of $0.235 per Class A ordinary share for the second quarter of 2026. This dividend will be paid on June 10, 2026, to shareholders who are on record as of May 15, 2026. The company, founded in 1996, specializes in acquiring biopharmaceutical royalties and funding innovation within the biopharmaceutical industry.
2026-04-02 22:10:26
Entities linked to Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold 34,791 Class A Ordinary Shares in open-market transactions on April 1, 2026, at a weighted average price of $48.3318 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025, indicating they were scheduled and not opportunistic. Despite these sales, Coyne and affiliated entities retain substantial holdings, suggesting a routine portfolio adjustment rather than a complete exit.
2026-04-01 20:38:59
Royalty Pharma plc director Bonnie L. Bassler was granted 815 Class A Ordinary Shares as an equity award, replacing a $37,500 quarterly retainer payment. The shares were issued at a reference price of $45.977 per share under the company’s 2020 Independent Director Equity Incentive Plan. Following this transaction, Bassler directly holds 73,947 Class A Ordinary Shares.
2026-04-01 19:41:04
Pablo Legorreta, founder and CEO of Royalty Pharma, revolutionized pharmaceutical funding by creating a model to purchase royalty streams on approved or late-stage drugs. This innovative approach provides immediate, non-dilutive capital to drug developers, accelerating medical innovation and generating significant returns for investors. Under his leadership, Royalty Pharma has become the world's largest buyer of pharmaceutical royalties, deploying over $25 billion and expanding across the entire drug development ecosystem.
2026-03-25 23:12:00
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares worth approximately $1.58 million on March 23, 2026, under a pre-arranged 10b5-1 trading plan. The shares were sold at a weighted average price of $45.5287, near Royalty Pharma's 52-week high, with InvestingPro analysis suggesting the stock is overvalued. This transaction follows other strategic moves by Royalty Pharma, including a financing agreement with Zymeworks Inc. and key appointments to bolster AI capabilities and global reach.
2026-03-25 21:40:06
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 34,791 Class A Ordinary Shares for approximately $1.58 million. The sales were conducted under a pre-arranged 10b5-1 trading plan with shares trading near their 52-week high, although InvestingPro analysis suggests the stock is currently overvalued. Following these transactions, Coyne retains significant indirect and direct holdings in the company.
